Interplay of reactive oxygen species and nitric oxide in the pathogenesis of experimental lead-induced hypertension

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 9, 2007, Pages 920-925

  Vaziri, N D ^a   Khan, M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Endothelial dysfunction; Nitric oxide; Oxidative stress; Pb; Toxic exposure

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROGEN PEROXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; LEAD; MALONALDEHYDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ADRENERGIC ACTIVITY; ARTERIAL PRESSURE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXTRACELLULAR SPACE; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; KIDNEY DISEASE; NONHUMAN; OXIDATIVE STRESS; REVIEW; SMOOTH MUSCLE FIBER; SYSTEMIC VASCULAR RESISTANCE;

ANIMALS; BLOOD PRESSURE; CYCLIC GMP; DISEASE MODELS, ANIMAL; GUANYLATE CYCLASE; HYPERTENSION; LEAD; NADPH OXIDASE; NEPHRITIS, INTERSTITIAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 34447526350     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04644.x     Document Type: Review

References (50)

1. Pirkle JL, Kaufmann RB, Brody DJ, Hickman T, Gunter EW, Paschal DC. Exposure of the US population to lead, 1991-94. Environ. Health Perspect. 1998 106 : 745 50.
2. Sharp DS, Osterloh J, Becker CE et al. Blood pressure and blood lead concentration in bus drivers. Environ. Health Perspect. 1988 78 : 131 7.
3. Harlan WR. The relationship of blood lead levels to blood pressure in the US population. Environ. Health Perspect. 1988 78 : 9 13.
4. Den Hond E, Nawrot T, Staessen JA. The relationship between blood pressure and blood lead in NHANES III. National Health and Nutritional Examination Survey. J. Hum. Hypertens. 2002 16 : 563 8.
5. Menditto A, Morisi G, Spagnolo A, Mencotti A. Association of blood lead to blood pressure in men aged 55-75 years: Effects of selected social and biochemical cofounders. Environ. Health Perspect. 1994 102 : 107 11.
6. Hu H, Aro A, Payton M et al. The relationship of bone and blood lead to hypertension. The normative aging study. JAMA 1996 275 : 1171 6.
7. Apostoli P, Maranelli G, Micciolo R. Is hypertension a confounding factor in the assessment of blood lead reference values? Sci. Total Environ. 1992 120 : 127 34.
8. Pirkle JL, Schwartz J, Landis JR, Harlan WR. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am. J. Epidemiol. 1985 121 : 246 58.
9. Rothenberg SJ, Kondrashov V, Manalo M et al. Increases in hypertension and blood pressure during pregnancy with increased bone lead levels. Am. J. Epidemiol. 2002 156 : 1079 87.
10. Glenn BS, Stewart WF, Links JM, Todd AC, Schwartz BS. The longitudinal association of lead with blood pressure. Epidemiology 2003 14 : 30 6.
11. Batuman V. Lead nephropathy, gout and hypertension. Am. J. Med. Sci. 1993 305 : 241 7.
12. Nash D, Magder L, Lustberg M et al. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA 2003 289 : 1523 32.
13. Staessen JA, Roels H, Lauwerys RR, Amery A. Low-level lead exposure and blood pressure. J. Hum. Hypertens. 1995 9 : 303 28.
14. Houston DK, Johnson MA. Lead as a risk factor for hypertension in women. Nutr. Rev. 1999 57 : 227 79.
15. Cheng Y, Schwartz J, Sparrow D, Aro A, Weiss ST, Hu H. Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: The normotensive aging study. Am. J. Epidemiol. 2001 153 : 164 71.
16. Hu H. Poorly controlled hypertension in a painter with chronic lead toxicity. Environ. Health Perspect. 2001 109 : 95 9.
17. Fleet JC. Bone lead as a risk factor for hypertension in men. Nutr. Rev. 1996 54 : 180 2.
18. Nilsson U, Attewell R, Christoffersson JO et al. Kinetics of lead in the bone and blood after the end of occupational exposure. Pharmacol. Toxicol. 1991 68 : 477 84.
19. Vaziri ND. Pathogenesis of lead-induced hypertension: Role of oxidative hypertension stress. J. Hypertens. 2002 20 (Suppl. S15 20.
20. Vaziri ND, Sica D. Lead-induced hypertension: Role of oxidative stress. Curr. Hypertens. Rep. 2004 6 : 314 20.
21. Khalil-Manesh F, Gonick HC, Weiler EW, Prins B, Weber MA, Purdy RE. Lead induced hypertension: Possible role of endothelial factors. Am. J. Hypertens. 1993 6 : 723 9.
22. Khalil-Manesh F, Gonick HC, Weiler EW et al. Effect of chelation treatment with dimercaptosuccinic acid (DMSA) on lead-related blood pressure changes. Environ. Res. 1994 65 : 86 99.
23. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND. Lead-induced hypertension: Interplay of nitric oxide and reactive oxygen species. Hypertension 1997 30 : 1487 92.
24. Ding Y, Vaziri ND, Gonick HC. Lead-induced hypertension. II. Response to sequential infusions of l-arginine, superoxide dismutase, and nitroprusside. Environ. Res. 1998 76 : 107 13.
25. Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: Effect of lazaroid therapy. Kidney Int. 1997 52 : 1042 6.
26. Dursun N, Arifoglu C, Suer C, Keskinol L. Blood pressure relationship to nitric oxide, lipid peroxidation, renal function, and renal blood flow in rats exposed to low lead levels. Biol. Trace Elem. Res. 2005 104 : 141 50.
27. Attri J, Dhawan V, Mahmood S, Pandhi P, Parwana HK, Nath R. Effect of vitamin C supplementation on oxidative DNA damage in an experimental model of lead-induced hypertension. Ann. Nutr. Metab. 2003 47 : 294 301.
28. Malvezzi CK, Moreira EG, Vassilieff I, Vassilieff VS, Cordellini S. Effect of l-arginine, dimercaptosuccinic acid (DMSA) and the association of l-arginine and DMSA on tissue lead mobilization and blood pressure level in plumbism. Braz. J. Med. Biol. Res. 2001 34 : 1341 6.
29. Vaziri ND, Ding Y, Ni Z. Nitric oxide synthase expression in the course of lead-induced hypertension. Hypertension 1999 34 : 558 62.
30. Vaziri ND, Ding Y, Ni Z. Compensatory upregulation of NO synthase isoforms in lead-induced hypertension: Reversal by an SOD-mimetic drug. J. Pharmacol. Exp. Ther. 2001 298 : 679 85.
31. Vaziri ND, Wang XQ. cGMP-mediated negative feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension 1999 34 : 1237 41.
32. Vaziri ND, Ding Y, Ni Z, Barton CH. Bradykinin downregulates whereas arginine analogues upregulate eNOS expression in coronary endothelial cells. J. Pharmacol. Exp. Ther. 2005 313 : 121 6.
33. Vaziri ND, Ding Y. Effect of lead on NO synthase expression in coronary endothelial cells: Role of superoxide. Hypertension 2001 37 : 223 6.
34. Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int. 1999 56 : 1492 8.
35. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res. 1999 85 : 753 66.
36. Vaziri ND, Rodriguez-Iturbe B. Role of oxidative stress and inflammation in the pathogenesis of hypertension. Nat. Clin. Pract. Nephrol. 2006 2 : 582 93.
37. Marques M, Millas I, Jimenez A et al. Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J. Am. Soc. Nephrol. 2001 12 : 2594 600.
38. Farmand F, Ehdaie A, Roberts CK, Sindhu RK. Lead-induced dysregulation of superoxide dismutases, catalase, glutathione peroxidase, and guanylate cyclase. Environ. Res. 2005 98 : 33 9.
39. Courtois E, Marques M, Barrientos A, Casado S, Lopez-Farre A. Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygenase-2. J. Am. Soc. Nephrol. 2003 14 : 1464 70.
40. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: Molecular and cellular mechanisms. Hypertension 2003 42 : 1075 81.
41. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ. Res. 2000 86 : 494 501.
42. Chabrashvili T, Tojo A, Onozato ML et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002 39 : 269 74.
43. Vaziri ND, Lin CY, Farmand F, Sindhu RK. Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension. Kidney Int. 2003 63 : 186 94.
44. Ni Z, Hou S, Barton CH, Vaziri ND. Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int. 2004 66 : 2329 36.
45. Ding Y, Gonick HC, Vaziri ND, Liang K, Wei L. Lead-induced hypertension: Increased hydroxyl radical production. Am. J. Hypertens. 2001 14 : 169 73.
46. Ding Y, Gonick HC, Vaziri ND. Lead promotes hydroxyl radical generation and lipid peroxidation in cultured aortic endothelial cells. Am. J. Hypertens. 2000 13 : 552 5.
47. Ramesh GT, Manna SK, Aggarwal BB, Jadhav AL. Lead exposure activates nuclear factor kappa B, activator protein-1, c-Jun N-terminal kinase and caspases in the rat brain. Toxicol. Lett. 2001 123 : 195 207.
48. Rodriguez-Iturbe B, Sindhu RK, Quiroz Y, Vaziri ND. Chronic exposure to low doses of lead results in renal infiltration of immune cells, apoptosis, NF-κB activation and overexpression of tubulointerstitial angiotensin II. Antioxid. Redox Signal. 2005 7 : 1269 74.
49. Rodriquez-Itrube B, Vaziri ND, Herrera J, Johnson RJ. Oxidative stress, renal infiltration of immune cells and salt-sensitive hypertension. All for one and one or all. Am. J. Physiol. Renal Physiol. 2004 286 : F606 16.
50. Carmignani M, Volpe AR, Boscolo P et al. Catecholamine and nitric oxide systems as targets of chronic lead exposure in inducing selective functional impairment. Life Sci. 2000 68 : 401 15.